Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | EBP | Q15125 | 1/20 | 0.76 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007452 | 0.91 | DHCR7 (0.92) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL6882681 | 0.90 | EBP (0.63) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL8185779 | 0.90 | EBP (0.63) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL13818486 | 0.90 | EBP (0.63) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL15503757 | 0.87 | MEN1 (1.00) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL28882522 | 0.86 | ALDH1A1 (0.66) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL15014573 | 0.86 | MEN1 (0.77) | MEN1KMT2ATDP1EBPDHCR7 | |
| SCHEMBL8203532 | 0.85 | PKM (0.88) | MEN1KMT2ALMNAPKMALDH1A1 | |
| SCHEMBL4537086 | 0.85 | PKM (0.88) | MEN1KMT2ALMNAPKMALDH1A1 | |
| SCHEMBL10724066 | 0.85 | PKM (0.88) | MEN1KMT2ALMNAPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143688-B | Preparation method of 3-piperidone compound | 江南大学 | 2025-03-11 | — | — | CN | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| CN-116143688-A | Preparation method of 3-piperidone compound | 江南大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-111233752-B | Decarboxylation in-situ methylation method of alkyl active carboxylic ester | 中国科学技术大学 | 2021-07-09 | — | — | CN | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-111233752-A | Decarboxylation in-situ methylation method of alkyl active carboxylic ester | 中国科学技术大学 | 2020-06-05 | — | — | CN | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | MEN1 4581/4885KMT2A 3213/4885TDP1 1240/4885 |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | MEN1 2546/4885KMT2A 2317/4885TDP1 1766/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | MEN1 4642/4885KMT2A 2032/4885TDP1 1944/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | MEN1 1464/4885KMT2A 2089/4885TDP1 2047/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | MEN1 1700/4885KMT2A 1380/4885TDP1 1296/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | MEN1 78/4885KMT2A 1442/4885TDP1 3393/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | MEN1 2994/4885KMT2A 2967/4885TDP1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.